Patent ID: 11859213
Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
Field: Biotechnology (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 2:
3. The method of claim 1, wherein one or both alleles of ETV2, NKX2-5, HandII, TBX5, MYF5, MYOD, MRF4, IL2Rgy/−, RAG2−/−, IL2Rg−/−;
RAG2−/−, IL2Rgy/−, RAG2−/−, IL2Rg+/−, RAG2+/−, IL2Rgy/+; RAG2+/—, IL2Rg+/−;
RAG2+/−, DGAT (diglyceride acyltransferase), ABCG2 (ATP-binding cassette sub-family G member 2), ACAN (aggrecan), AMELY (amelogenin, y-linked), BLG (progestagen-associated endometrial protein), BMP 1B (FecB) (bone morphogenetic protein receptor, type 1B), DAZL (deleted in azoospermia like), Eif4GI (eukaryotic translation initiation factor 4 gamma, 1), GDF8 (growth/differentiation factor 8), Horn-poll locus, IGF2 (insulin-like growth factor 2), CWC15 (CWC15 spliceosome associated protein), KissR/GRP54 (kisspeptin), OFD1Y (Y-linked oral-facial-digital syndrome 1 pseudogene), p65 (v-rel reticuloendotheliosis viral oncogene homolog A), PRLR (prolactin receptor), Prmd14 (PR domain containtin 14), PRNP (prion protein), Rosa, Socs2 (suppressor of cytokine signaling 2), SRY (sex determining region of Chr Y), ZFY (zinc finger protein, y-linked), β-lactoglobulin, callipyg (CLPG), MODY 1 (HNF4α) (hepatocyte nuclear factor 4, alpha), MODY 2 (GCK) (glucokinase), MODY 3 (HNF1α) (hepatocyte nuclear factor 4, alpha), MODY 4, MODY 5 (HNF-1β) (HNF1 homeobox B), MODY 6 (eurogenic differentiation 1), MODY 7 (KLF11) (Kruppel-like factor 11), MODY 8 (CEL) (carboxyl ester lipase), MODY 9 (PAX4) (paired box 4), MODY 10 (INS) (insulin), MODY 11 (BLK) (BLK proto-oncogene, Src family tyrosine kinase), APC (adenomatosis polyposis coli), ApoE (apolipoprotein E), DMD (dystrophin muscular dystrophy), GHRHR (growth hormone releasing hormone receptor), HR (hair growth associated), HSD11B2 (hydroxysteroid (11-beta) dehydrogenase 2), LDLR (low density lipoprotein receptor), NF1 (neurofibromin 1), NPPA (natriuretic peptide A), NR3C2 (nuclear receptor subfamily 3, group C, member 2), p53 (cellular tumor antigen p53-like), PKD1 (polycystic kidney disease 1), Rbm20 (RNA binding motif protein 20), SCNN1G (sodium channel, non-voltage gated 1 gamma subunit), tP53 (tumor protein p53), FAH (fumarylacetoacetate hydrolase), HBB (hemoglobin beta), IL2RG (interleukin 2 receptor, gamma chain), GGTA (bifunctional cephalosporin acylase/gamma-glutamyltranspetidase), VASA (vasa protein), MIWI (piwi-like RNA-mediated gene silencing 1), PIWI (CG6122 gene product from transcript CG6122-RA), DCAF17 (DDB1 and CUL4 associated factor 17), VDR (vitamin D receptor), PNPLA1 (patatin-like phospholipase domain containing 1), HRAS (Harvey rat sarcoma viral oncogene homolog), Telomerase-vert, DSP (desmoplakin), SNRPE (small nuclear ribonucleoprotein polypeptide E), RPL21 (ribosomal protein), LAMA3 (laminin, alpha 3), UROD (uroporphyrinogen decarboxylase), EDAR (ectodysplasin-A receptor), OFD1 (oral-facial-digital syndrome 1), PEX7 (peroxisomal biogenesis factor 7), COL3A1 (collagen, type III, alpha 1), ALOX12B (arachidonate 1201ipoxygenase 12R type), HLCS (holocarboxylase synthetase (biotin-(proprionyl-CoA-carboxylase)ATP-hydrolysing)) ligase)), NIPAL4 (NIPA-like domain containing 4), CERS3 (ceramide synthase 3), ANTXR1 (anthrax toxin receptor 1), B3GALT6 (UDP-Gal: betaGA1 beta 1,3 galactosyltransferase polypeptide 6), DSG4 (desmoglein 4), UBR1 (ubiquitin protein ligase E3 component n-recognin 1), CTC1 (CTS telomere maintenance complex component 1), MBTPS2 (membrane-bound transcription factor peptidase, site 2), UROS (uroporphyrinogen III synthase), ABHDS (abhydrolase domain containing 5), NOP10 (NOP10 ribonucleoprotein), ALMS1 (Alstrom syndrome protein 1), LAMB3 (laminin, beta 3), EOGT (EGF domain-specific 0-linked N-acetylglucosamine (GlcNAc)), SAT1 (spermindine/spermine N1-acetyltransferase 1), RBPJ (recombination signal binding protein for immunoglobulin kappa J region), ARHGAP31 (Rho GTPase activating protein 31), ACVR1 (activin A receptor, type I), IKBKG (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma), LPAR6 (lysophosphatidic acid receptor 6), HR (hair growth associated), ATR (ATR serine/threonine kinase), HTRA1 (HtrA serine peptidase 1), AIRE (autoimmune regulator), BCS1L (BC1 (ubiquinol-cytochrome c reductase) synthesis-like), MCCC2 (methylcrotonoyl-CoA carboxylase 2 (beta)), DKC1 (dyskeratosis congenital 1, dyskerin), PORCN (porcupine homolog), EBP (emopamil binding protein (sterol isomerase)), SLITRK1 (SLIT and NTRK-like family, member 1), BTK (Bruton agammaglobulinemia tyrosine kinase), DOCK6 (dedicator of cytokinesis 6), APCDD1 (adenomatosis polyposis coli down-regulated 1), ZIP4 (zinc transporter 4 precursor), CASR (calcium-sensing receptor), TERT (telomerase reverse transcriptase), EDARADD (EDAR (ectodysplasin-A receptor)-associated death domain), ATP6VOA2 (ATPase, H+transporting, lysosomal VO subunit a2), PVRL1 (poliovirus receptor-related 1 (herpesvirus entry mediator C)), MGP (matrix Gla protein), KRT85 (keratin 85, type II), RAG2 (recombination activating gene 2), RAG-1 (recombination activating gene 1), ROR2 (receptor tyrosine kinase-like orphan receptor 2), CLAUDIN1 (claudin 7), ABCA12 (ATP-binding cassette, subfamily A (ABC1), member 12), SLA-DRA1 (MHC class II DR-alpha), B4GALT7 (xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7), COL7A1 (collagen type VII, alpha 1), NHP2 (NHP2 ribonucleoprotein), GNA11 (guanine nucleotide binding protein (g protein), alpha 11 (Gq class)), WNTSA (wingless-typ MMTV integration site family member 5A), USB1 (U6 snRNA biogenesis 1), LMNA (lamin A/C), EPS8L3 (EPS8-like 3), NSDHL (NAD(P) dependent steroid dehydrogenase-like), TRPV3 (transient receptor potential cation channel subfamily V, member 3), KRAS (Kirsten rat sarcoma viral oncogene homolog), TINF2 (TERF1-interacting nuclear factor 2), TGM1 (tranglutaminase 1), DCLRE1C (DNA cross-link repair 1C), PKP1 (plakophilin 1), WRAP53 (WD repeat containing antisense to TP53), KDMSC (lysine (k) specific demethylase 5C), ECM1 (extracellular matrix protein 1), TP63 (tumor protein p63), KRT14 (keratin 14), RIPK4 (receptor-interacting serine-threonine kinase 4), PRKDC (protein kinase, DNA activated, catalytic polypeptide), BCL11a (B-cell CLL/lymphoma 11A (zinc finger protein)), BMI1 (BMI1 proto-oncogene, polycomb ring finger), CCRS (chemokine (C-C motif) receptor 5 (gene/pseudogene)), CXCR4 (chemokine (C-X-C motif) receptor 4), DKK1 (dickkopf WNT signaling pathway inhibitor 1), ETV2 (ets variant 2), FLI1 (Fli-1 proto-oncogene, ETS transcription factor), FLK1 (kinase insert domain receptor), GATA2 (GATA binding protein 2), GATA4 (GATA binding protein 4), MYFS (myogenic factor 5), MYOD1 (myogenic differentiation 1), MYOG (myogenin), NKX2-5 (NK2 homeobox 5), NR4A2 (nuclear receptor subfamily 4, group A, member 2), PAX3 (paired box 3), PITX3 (paired-like homeodomain transcription factor 3), Runx1 (runt-related transcription factor 1), RAG2 (recombination activating gene 2), GGTA (bifunctional cephalosporin acylase/gamma-glutamyhtranspeptidase), HANDII (heart- and neural crest derivative expressed protein 2), TBXS (T-box 5), ETV2 (ets variant 2), TBX4 (T-box 4), ID2 (inhibitor of DNA binding 2), SOX2 (SRY (sex determining region Y)-box 2), TTF1/NKX2-1 (NK2 homeobox 1), MESP1 (mesoderm posterior 1), NKX2-5 (HK2 homeobox 5), FAH (fumarylacetoacetate hydrolase), SALL1, PRKDC (protein kinase, DNA activated, catalytic polypeptide), RUNX1 (runt related transcription factor 1), FLI1 (fli-1 proto-oncogene, ETS transcription factor), PITX3 (paired-like homeodomain transcription factor 3, DKK1 (dickkopf WNT signaling pathway inhibitor 1), FLK1 (kinase insert domain receptor), BCL11A (B-cell CLL/lymphoma 11A (zinc finger protein), RAG2 (recombination activating gene 2), RAG1 (recombination activating gene 1), IL2RG (interleukin 2 receptor, gamma chain), c-KIT/SCFR (v-kit hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), BMI1 (BMI1 proto-oncogene polycomb ring finger), TBXS (T-box 5) and combinations thereof are disrupted in said non-human embryo.